Epidemiological Data on Anaphylaxis in French Emergency Departments.


Journal

Journal of investigational allergology & clinical immunology
ISSN: 1018-9068
Titre abrégé: J Investig Allergol Clin Immunol
Pays: Spain
ID NLM: 9107858

Informations de publication

Date de publication:
2019
Historique:
pubmed: 10 11 2018
medline: 23 2 2020
entrez: 10 11 2018
Statut: ppublish

Résumé

Although anaphylaxis has been considered a priority public health issue in the world allergy community, epidemiological data on morbidity and mortality remain suboptimal. We performed the first multicenter epidemiological study in French emergency departments (EDs). The study covered 7 EDs over a period of 1 year. The objectives were to identify areas that are amenable to change and to support ongoing national and international efforts for better diagnosis, management, and prevention of anaphylaxis. Ours was a descriptive study based on data routinely reported to French institutional administrative databases from 7 French public health institutions in the Lorraine region between January and December 2015. Data were collected based on the anaphylaxisrelated codes of the International Classification of Diseases (ICD)-10, and cases were clinically validated as anaphylaxis. Of the 202 079 admissions to the EDs, 4817 had anaphylaxis-related codes; of these, 323 were clinically validated as anaphylaxis. Although 45.8% were severe, adrenaline was prescribed in only 32.4% of cases. Of the 323 cases, 57.9% were subsequently referred for an allergy work-up or evaluation (after or during hospitalization), and 17.3% were prescribed autoinjectable epinephrine. Our results highlight an urgent need for improved public health initiatives with respect to recognition and treatment of anaphylaxis. We flag key problems that should be managed in the coming years through implementation of national and international actions.

Sections du résumé

BACKGROUND BACKGROUND
Although anaphylaxis has been considered a priority public health issue in the world allergy community, epidemiological data on morbidity and mortality remain suboptimal. We performed the first multicenter epidemiological study in French emergency departments (EDs). The study covered 7 EDs over a period of 1 year. The objectives were to identify areas that are amenable to change and to support ongoing national and international efforts for better diagnosis, management, and prevention of anaphylaxis.
METHODS METHODS
Ours was a descriptive study based on data routinely reported to French institutional administrative databases from 7 French public health institutions in the Lorraine region between January and December 2015. Data were collected based on the anaphylaxisrelated codes of the International Classification of Diseases (ICD)-10, and cases were clinically validated as anaphylaxis.
RESULTS RESULTS
Of the 202 079 admissions to the EDs, 4817 had anaphylaxis-related codes; of these, 323 were clinically validated as anaphylaxis. Although 45.8% were severe, adrenaline was prescribed in only 32.4% of cases. Of the 323 cases, 57.9% were subsequently referred for an allergy work-up or evaluation (after or during hospitalization), and 17.3% were prescribed autoinjectable epinephrine.
CONCLUSION CONCLUSIONS
Our results highlight an urgent need for improved public health initiatives with respect to recognition and treatment of anaphylaxis. We flag key problems that should be managed in the coming years through implementation of national and international actions.

Identifiants

pubmed: 30411700
doi: 10.18176/jiaci.0348
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

357-364

Auteurs

J Corriger (J)

Allergy Department, Hospital Emile Durkheim, Epinal, France.
Internal Medicine and Clinical Immunology Department, University Hospital, Vandoeuvre-lès-Nancy, France.

E Beaudouin (E)

Allergy Department, Hospital Emile Durkheim, Epinal, France.

R Rothmann (R)

Emergency Department, Hospital Mercy-Metz, Ars-Laquenexy, France.

E Penven (E)

Occupational Diseases Department, University Hospital, Vandoeuvre-lès-Nancy, France.
Division of Allergy, Dermatology Department, University Hospital, Vandoeuvre-lès-Nancy, France.

Q Haumonte (Q)

Allergy Department, Hospital Emile Durkheim, Epinal, France.

H Thomas (H)

Allergy Department, Hospital Emile Durkheim, Epinal, France.

J Picaud (J)

Allergy Department, Hospital Emile Durkheim, Epinal, France.

V M Nguyen-Grosjean (VM)

Allergy Department, Hospital Emile Durkheim, Epinal, France.

J Corriger-Ippolito (J)

Division of Allergy, Dermatology Department, University Hospital, Vandoeuvre-lès-Nancy, France.
Emergency Department, University Hospital, Vandoeuvre-lès-Nancy, France.

F Braun (F)

Emergency Department, Hospital Mercy-Metz, Ars-Laquenexy, France.

M De Talancé (M)

Emergency Department, Hospital Emile Durkheim, Epinal, France.

B Auburtin (B)

Pediatric Emergency Department, Hospital Emile Durkheim, Epinal, France.

P Atain-Kouadio (P)

Emergency Department, University Hospital, Vandoeuvre-lès-Nancy, France.

A Borsa-Dorion (A)

Pediatric Emergency Department, University Hospital, Vandoeuvre-lès-Nancy, France.

D Baugnon (D)

Emergency Department, Hospital of Verdun-Saint-Mihiel, Verdun, France.

M De Carvalho (M)

Biology and Immunology Laboratory, University Hospital, Vandoeuvre-lès-Nancy, France.

R Jaussaud (R)

Internal Medicine and Clinical Immunology Department, University Hospital, Vandoeuvre-lès-Nancy, France.

P L Nguyen-Thi (PL)

Clinical Research Platform, ESPRI-BioBase Unit, University Hospital, Vandoeuvre-lès-Nancy, France.

P E Bollaert (PE)

Medical Intensive Care Unit, University Hospital, Nancy, France.

P Demoly (P)

Division of Allergy, Department of Pulmonology, University of Montpellier, France and Sorbonne University, INSERM, IPLESP, EPAR team, Paris, France.

L K Tanno (LK)

Division of Allergy, Department of Pulmonology, University of Montpellier, France and Sorbonne University, INSERM, IPLESP, EPAR team, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH